Fenobam - Autism Therapeutics

Drug Profile

Fenobam - Autism Therapeutics

Alternative Names: AT002; Fenobam hydrochloride; NPL-2009

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FRAXA Research Foundation; Neuropharm
  • Class Chlorobenzenes; Imidazoles; Small molecules; Urea compounds
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • No development reported Fragile X syndrome

Most Recent Events

  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for Fragile X syndrome in USA (PO)
  • 21 Dec 2011 Autism Therapeutics acquires Neuropharm
  • 07 Jan 2009 Pharmacokinetics, safety and efficacy data from a phase I/II trial in Fragile X Syndrome released by Neuropharma ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top